27091-83-4

Basic information

• Product Name: Butanoic acid, 4-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)oxy]-, ethyl ester
• Synonyms: 4-phthalimidooxy-butyric acid ethyl ester;ethyl 4-(1,3-dioxo-1,3-dihydroisoindol-2-yloxy)butyrate;4-(1,3-Dioxo-1,3-dihydro-isoindol-2-yloxy)-butyric acid ethyl ester;4-phthalimidooxy-butanoic acid ethyl ester;Ethyl 4-(phthalimidooxy)butyrate
• CAS NO: 27091-83-4
• Molecular Formula: C14H15NO5
• Molecular Weight: 277.27300
• Mol File: 27091-83-4.mol
• Article Data: 5

Chemical Properties

• Melting Point: 48.5 °C (isopropyl alcohol)
• CAS DataBase Reference: Butanoic acid, 4-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)oxy]-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Butanoic acid, 4-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)oxy]-, ethyl ester(27091-83-4)
• EPA Substance Registry System: Butanoic acid, 4-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)oxy]-, ethyl ester(27091-83-4)

Safety Data

• Hazardous Substances Data: 27091-83-4(Hazardous Substances Data)

Upstream product

• 524-38-9 N-hydroxyphthalimide 
• 2969-81-5 Ethyl 4-bromobutyrate 

Downstream Products

• 180865-38-7 4-[1-Phenyl-1-pyrimidin-2-yl-meth-(E)-ylideneaminooxy]-butyric acid ethyl ester 
• 180865-44-5 4-[1-Phenyl-1-pyrimidin-2-yl-meth-(Z)-ylideneaminooxy]-butyric acid ethyl ester 

Relevant articles and documents

4-OXO-N-(4-HYDROXYPHENYL)RETINAMIDE DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER

The present invention relates to a compound having formula (I) below or a pharmaceutically acceptable salt thereof: wherein: X is -COOH or NH2; R is a straight or branched C1-C10 alkylene chain; and R1 is H, str

5-SUBSTITUTED-2-PHENYLAMINO-BENZAMIDE AS MEK INHIBITOR

An objective of the present invention is to provide compounds that exhibit strong MEK-inhibiting activity and are stable in vivo and soluble in water, which can be used as preventive or therapeutic agents for proliferative diseases. The compounds of the present invention and pharmaceutically acceptable salts thereof are represented by the following formula (1): [where R1, R2, R3, R4, and X are the same as defined in the present patent application].

On the bioisosteric potential of diazines: Diazine analogues of the combined thromboxane A2 receptor antagonist and synthetase inhibitor ridogrel

In this SAR study the bioisosteric potential of diazines in the field of combined antithrombotic thromboxane A2 synthetase inhibitors and receptor antagonists was investigated. In this context, two series of (E)- and (Z)- ω-[[(aryldiazinylmethy